Singing and COPD: a pilot randomised controlled trial

ISRCTN ISRCTN42943709
DOI https://doi.org/10.1186/ISRCTN42943709
Secondary identifying numbers Protocol 1
Submission date
04/12/2018
Registration date
08/05/2019
Last edited
15/08/2022
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Respiratory
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Chronic obstructive pulmonary disease (COPD) is a long-term and progressive respiratory disease which negatively affects people’s health and wellbeing. The condition deteriorates over time, and there is no cure. However, there is evidence that activities like regular exercise and singing can improve breathlessness and general health and wellbeing. Previous research has shown positive benefits of singing for respiratory illness, but two recent reviews of the evidence highlights the limitations of previous research and the need for further larger-scale controlled studies with follow-up. The aim of this study is to build on previous research and undertake a larger-scale controlled study of the effects of regular group singing for people with COPD. A new feature of the study will be the direct assessment of patients’ patterns of breathing to investigate whether regular singing serves to encourage stronger and more consistent use of the diaphragm to support breathing.

Who can participate?
Adult patients with moderate to very severe COPD

What does the study involve?
Participants are assessed using a number of short questionnaires to assess health status and psychological wellbeing. In addition, lung function is assessed. The focus of interest is on the extent to which patients engage in shallow upper chest breathing, or engage their diaphragm is deeper abdominal breathing. Following the assessment, half of the participants are selected at random to participate in a singing programme and half receive usual care. The singing programme takes place over ten 90-minute sessions. The programme involves breathing exercises and songs which encourage controlled breathing and progressive extension of the time taken to breathe out. Following the end of the singing programme, participants are assessed for a second time. There is then a follow-up period of three months during which no singing activity takes place, and the participants are assessed for a third time to see whether any changes observed immediately following the intervention are maintained.

What are the possible benefits and risks of participating?
On the basis of previous research, participants are expected to gain an increased sense of personal and social wellbeing from participating in an enjoyable and stimulating group activity. If this is the case, we should see this reflected in answers given on the structured questionnaires that will be employed in the study. They may also find that regular singing teaches techniques of breathing which can help them manage their breathing difficulties more effectively. This potential outcome will be assessed using a validated COPD health questionnaire and direct assessments of lung function. A further benefit for all participants, whether in the intervention or control group, is the satisfaction of taking part in a scientific study aimed at improving the treatment of COPD. Previous research indicates that there are no risks associated with regular singing for people with COPD, and no side effects.

Where is the study run from?
The study is a collaboration between Canterbury Christ Church University, the University of Kent and Medway Community Healthcare who provide secondary support services for people with COPD. Patients will be recruited through Medway Community Healthcare Respiratory Team. The intervention will take place in a community venue in Medway UK, with singing sessions taking place weekly for ten weeks. Assessments will take place in the Sport Sciences laboratory of the University of Kent at Medway Park Sports Centre.

When is the study starting and how long is it expected to run for?
March 2018 to March 2020

Who is funding the study?
The study is being funded by Oak Foundation and supported by Canterbury Christ Church University and the University of Kent (UK)

Who is the main contact?
Prof. Persephone Sextou, persephone.sextou@canterbury.ac.uk

Contact information

Prof Persephone Sextou
Scientific

Sidney De Haan Research Centre for Arts and Health
65-69 Tontine Street
Folkestone
CT20 1JR
United Kingdom

Email persephone.sextou@canterbury.ac.uk

Study information

Study designSingle-blinded randomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Community
Study typeQuality of life
Participant information sheet Not available in web format. Please use contact details to request a participant information sheet.
Scientific titleSinging and COPD: a pilot randomised controlled trial to assess the effects of a structured 10-week programme of singing on the health-related quality of life of patients with COPD, compared with usual treatment, six-months post-baseline assessment
Study acronymSinging and COPD
Study objectivesNo change occurs in COPD-specific health status, following ten weeks of regular, weekly singing at the primary end point for the trial six months post-baseline
Ethics approval(s)Approved 19/02/2019, London – Queens Square ethics committee (Friends Meeting House, Euston, NW1 2BJ; 0207 104 8061; NRESCommittee.London-QueenSquare@nhs.net), ref: 19/LO/0159
Health condition(s) or problem(s) studiedChronic obstructive pulmonary disease (COPD)
InterventionRandomisation will be conducted by a secure remote randomisation service independent of the research team. Randomisation will employ random permuted blocks of variable length with stratification by sex and COPD severity.

Intervention: a structured and progressive programme of group singing for participants with COPD delivered over 10 weeks in sessions lasting 90 minutes, supplemented by home practice between sessions supported by printed and audio-visual material.

The participants in the control condition will receive treatment as usual (TAU).

Participants will be assessed at baseline using a number of validated, short questionnaires to assess health status and psychological wellbeing. In addition, lung function will be assessed using standardised spirometry and a new technique which assesses patterns of breathing. The focus of interest is on the extent to which patients engage in shallow upper chest breathing, or engage their diaphragm is deeper abdominal breathing. Following baseline assessment, half of the participants will be selected at random to participate in a singing programme and half will receive usual care. The singing programme will be implemented over 10 90-minute sessions. The programme will involve breathing exercises and songs which will encourage controlled breathing and progressive extension of the time taken to breathe out. Following the end of the singing programme, participants will be assessed for a second time. There will then be a follow up period of 3 months during which no singing activity will take place, and the participants will be assessed for a third time to see whether any changes observed immediately following the intervention are maintained.
Intervention typeBehavioural
Primary outcome measureQuality of life assessed with the COPD Assessment Test (CAT) at baseline, three months following the ten-week intervention, and then after a further three months.
Secondary outcome measuresMeasured at baseline, three months following the ten-week intervention, and then after a further three months:
1. Breathlessness assessed using mMRC self-completion questionnaire
2. Physical health related quality of life and mental health related quality of life assessed using SF-36 v2 self-completion questionnaire
3. Generalised anxiety disorder assessed by GAD-7 (self-completion questionnaire)
4. Depression assessed by PHQ-9 (self-completion questionnaire)
5. Lung function and patterns of breathing assessed by standardised spirometry and structured light plethysmography
6. Functional exercise measured by the standardised six-minute walk test
Overall study start date01/03/2018
Completion date31/03/2020

Eligibility

Participant type(s)Patient
Age groupSenior
SexBoth
Target number of participants100
Total final enrolment36
Key inclusion criteriaThe trial will be open to patients:
1. With a diagnosis of COPD who have received pulmonary rehabilitation (or in receipt during the recruitment period)
2. Willing to undergo the collection of assessments planned
3. Willing to be randomised to either the intervention or control group
4. Able to attend one of the two groups planned (given the proposed day and time)
Key exclusion criteria1. Are unable to give informed consent
2. Have comorbid conditions that make participation difficult
3. Are unable to travel independently to the venues
4. Are not sufficiently fluent in English to complete the questionnaires employed
Date of first enrolment18/03/2019
Date of final enrolment09/03/2020

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Medway Community Healthcare
Bailey Drive
Gillingham
ME8 0PZ
United Kingdom

Sponsor information

Canterbury Christ Church University
University/education

North Holmes Road
Canterbury
CT1 1QU
England
United Kingdom

Phone +44 (0)1227 767700
Email douglas.macinnes@canterbury.ac.uk
Website https://www.canterbury.ac.uk/
ROR logo "ROR" https://ror.org/0489ggv38

Funders

Funder type

Charity

Oak Foundation
Private sector organisation / Trusts, charities, foundations (both public and private)
Alternative name(s)
Oak Foundation USA, Oak Philanthropy (US) Inc.
Location
United States of America
Canterbury Christ Church University
Private sector organisation / Universities (academic only)
Location
United Kingdom

Results and Publications

Intention to publish date01/07/2020
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planThe study protocol will be published on completion of the trial. The researchers plan to publish the primary findings from the trial in a high-impact peer reviewed journal. Additional publications will report on qualitative findings from the trial.
IPD sharing planFollowing publication of the trial results, all anonymised participant level data will be available to university researchers for secondary analysis. Participant consent given. Requests should be made in writing to the Head of Research, Faculty of Health and Wellbeing, Canterbury Christ Church University, North Holmes Road, Canterbury, Kent CT1 1QE, UK. Data will be available as an SPSS file for one year post-publication of the trial.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol file version 1 18/12/2018 15/08/2022 No No
Results article 01/05/2022 15/08/2022 Yes No
Results article Implementation and evaluation 01/05/2022 15/08/2022 Yes No
Results article Participant experiences 01/05/2022 15/08/2022 Yes No
HRA research summary 28/06/2023 No No

Additional files

ISRCTN42943709_Protocol_v1_18Dec2018.pdf

Editorial Notes

15/08/2022: The following changes have been made:
1. Publication references added.
2. Protocol file uploaded.
3. The scientific contact has been changed and the public contact deleted.
07/04/2020: The following changes were made to the trial record:
1. The recruitment end date was changed from 30/06/2019 to 09/03/2020.
2. The total final enrolment was added.
10/05/2019: Internal review.